Drug intelligence / Profile preview

MERS-CoV recombinant vaccine

Development stage: Preclinical
Lead developer: Techinvention Lifecare
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MERS-CoV recombinant vaccine is a protein subunit vaccine candidate being developed by Techinvention Lifecare for the prevention of Middle East Respiratory Syndrome (MERS). The vaccine utilizes recombinant protein technology to express key antigens of the MERS-CoV virus, such as the spike protein or its receptor-binding domain, to stimulate the production of neutralizing antibodies and cellular immune responses. It is currently in the preclinical (R&D) stage of development as part of the company's portfolio targeting emerging infectious diseases and "One Health" initiatives.

Other names: MERS-CoV recombinant protein vaccine

Targets

MERS-CoV S (MERS-CoV spike glycoprotein)

Beyond the preview

Go deeper on MERS-CoV recombinant vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MERS-CoV recombinant vaccine.

Explore the full profile